Head and Neck Cancer Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People diagnosed with squamous cell carcinoma (a type of cancer) in the head and neck area, specifically in the moist inner lining of these areas, but not in the nasopharynx (the upper part of the throat behind the nose)
- People whose scans show visible signs of active disease
- People whose treatment plan involves radiation therapy only, with the goal of curing the cancer
- People aged 18 years or older
- To be eligible for the second special imaging scan in the study: people whose first study scan showed the tumour absorbing enough of the imaging substance (a minimum uptake level of 2.5 on the scan reading)
Who may not be able to join:
- People with nasopharynx cancer (cancer in the upper part of the throat behind the nose)
- People with squamous cell carcinoma affecting the skin of the head and neck
- People whose cancer has already spread to other parts of the body, or where spreading is found on a chest scan taken at the start of the study
- People who have had another cancer diagnosis within the last 5 years (with some exceptions — confirm with trial site)
- People who have received chemotherapy in the last 5 years, or who are currently receiving chemotherapy or certain targeted drug therapies
- People who have previously had radiation therapy to the head or neck area
- People who are unable to lie flat on their back for the duration of the study procedures
- People who are pregnant
- People who are unable to give informed consent to participate
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: John J Kim, MD, The Princess Margaret Cancer Foundation
Phone: 416 946 4501
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Measure rate constant of 18F-FDG uptake in tumour and normal tissue with dynamic PET scanning before radiotherapy.
Can't join this trial?
Data last synced from ClinicalTrials.gov: 8 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.